Amphastar Pharmaceuticals (AMPH) stock price, revenue, and financials

Amphastar Pharmaceuticals market cap is $861.1 m, and annual revenue was $322.36 m in FY 2019

$861.1 M

AMPH Mkt cap, 29-May-2020

$84.7 M

Amphastar Pharmaceuticals Revenue Q1, 2020
Amphastar Pharmaceuticals Gross profit (Q1, 2020)36.8 M
Amphastar Pharmaceuticals Gross profit margin (Q1, 2020), %43.5%
Amphastar Pharmaceuticals Net income (Q1, 2020)3.5 M
Amphastar Pharmaceuticals EBIT (Q1, 2020)7.5 M
Amphastar Pharmaceuticals Cash, 31-Mar-202054.8 M
Amphastar Pharmaceuticals EV872.9 M

Amphastar Pharmaceuticals Revenue

Amphastar Pharmaceuticals revenue was $322.36 m in FY, 2019

Embed Graph

Amphastar Pharmaceuticals Revenue Breakdown

Embed Graph

Amphastar Pharmaceuticals revenue breakdown by business segment: 94.1% from Finished pharmaceutical products and 5.9% from Active Pharmaceutical Ingredients

Amphastar Pharmaceuticals Income Statement

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

210.5m251.5m255.2m240.2m294.7m322.4m

Revenue growth, %

20%1%

Cost of goods sold

159.2m174.2m151.0m149.4m187.7m190.4m

Gross profit

51.3m77.3m104.2m90.8m107.0m131.9m

Gross profit Margin, %

24%31%41%38%36%41%

Sales and marketing expense

5.6m5.5m5.5m6.5m8.2m12.8m

R&D expense

28.4m37.1m41.2m43.4m57.6m68.9m

General and administrative expense

34.8m41.5m41.8m44.5m49.9m50.3m

Operating expense total

69.2m84.2m88.5m91.7m115.6m132.0m

EBIT

(18.0m)(6.9m)15.7m(895.0k)(8.6m)(39.0k)

EBIT margin, %

(9%)(3%)6%0%(3%)0%

Interest expense

165.0k3.5m746.0k2.5m1.3m

Interest income

243.0k315.0k270.0k425.0k456.0k997.0k

Pre tax profit

(18.1m)(10.4m)14.9m1.6m(9.9m)60.2m

Income tax expense

(7.4m)(7.6m)4.4m(2.9m)(3.3m)13.7m

Net Income

(10.7m)(2.8m)10.5m4.5m(5.7m)46.5m

Quarterly

USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Revenue

49.0m59.7m56.9m53.9m63.9m59.4m68.0m64.2m56.7m65.2m57.9m58.4m71.0m75.5m79.8m79.0m80.1m84.7m

Cost of goods sold

34.0m47.9m43.6m40.5m46.3m34.5m36.3m36.6m33.8m38.4m37.3m41.3m44.9m46.3m48.9m46.7m44.9m47.9m

Gross profit

15.0m11.8m13.3m13.3m17.6m24.9m31.7m27.6m22.8m26.7m20.6m17.1m26.2m29.3m30.9m32.4m35.3m36.8m

Gross profit Margin, %

31%20%23%25%28%42%47%43%40%41%36%29%37%39%39%41%44%43%

Sales and marketing expense

1.4m1.5m1.5m1.5m1.2m1.4m1.3m1.3m1.5m1.6m1.8m1.7m1.9m3.1m3.0m3.2m3.3m

R&D expense

6.0m8.6m6.6m10.7m11.1m8.4m10.5m9.7m11.3m10.7m10.0m14.3m15.5m11.3m14.6m16.0m18.6m15.3m

General and administrative expense

8.6m9.6m12.5m11.3m9.0m10.9m9.5m10.8m11.3m12.2m11.7m11.0m11.7m13.4m16.3m12.4m11.0m10.7m

Operating expense total

16.2m19.6m20.5m23.6m21.3m20.8m21.4m21.8m21.4m24.6m23.5m27.0m29.0m26.7m34.1m31.4m32.8m29.3m

EBIT

(1.2m)(7.8m)(7.3m)(10.3m)(3.7m)4.1m10.3m5.8m1.4m2.2m(2.8m)(9.9m)(2.9m)2.6m(3.2m)973.0k2.4m7.5m

EBIT margin, %

(2%)(13%)(13%)(19%)(6%)7%15%9%2%3%(5%)(17%)(4%)3%(4%)1%3%9%

Interest expense

704.0k167.0k1.1m31.0k528.0k259.0k578.0k204.0k100.0k988.0k829.0k888.0k1.3m124.0k461.0k60.1m822.0k

Interest income

32.0k94.0k92.0k65.0k83.0k74.0k50.0k63.0k91.0k87.0k124.0k124.0k106.0k105.0k148.0k143.0k450.0k153.0k

Pre tax profit

(1.9m)(8.0m)(6.2m)(10.2m)(4.3m)3.8m9.8m6.0m1.5m3.2m(2.0m)(9.0m)(4.1m)2.6m(3.6m)61.1m1.6m5.8m

Income tax expense

(696.0k)(2.6m)(5.5m)(3.6m)(1.3m)1.3m2.9m2.1m611.0k1.2m(2.2m)(1.8m)(1.3m)958.0k(1.5m)14.2m598.0k2.3m

Net Income

(1.2m)(5.4m)(665.0k)(6.6m)(3.0m)2.5m6.9m3.9m893.0k2.0m175.0k(7.2m)(2.8m)1.6m868.0k47.8m1.3m3.5m

Amphastar Pharmaceuticals Balance Sheet

Annual

usdY, 2012Y, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

50.2m53.6m67.8m66.1m72.4m65.6m86.3m73.7m

Accounts Receivable

22.9m33.2m26.8m36.0m52.2m45.4m

Prepaid Expenses

9.8m5.5m9.5m

Inventories

118.4m63.6m69.3m110.5m

Current Assets

198.0m175.9m184.1m187.8m220.3m255.2m

PP&E

138.3m142.2m152.9m185.3m210.4m233.9m

Goodwill

42.6m39.9m50.3m45.1m42.3m41.2m

Total Assets

389.4m390.1m427.7m454.7m513.6m587.0m

Accounts Payable

10.2m13.9m16.2m16.6m31.3m25.1m

Short-term debt

6.3m18.2m10.9m

Current Liabilities

62.6m60.0m60.6m67.2m106.8m90.0m

Long-term debt

40.8m32.0m55.7m

Total Debt

47.2m50.2m66.6m

Total Liabilities

98.5m117.3m149.2m159.4m

Common Stock

5.0k5.0k5.0k

Additional Paid-in Capital

220.7m247.8m283.1m313.9m344.4m367.3m

Retained Earnings

63.1m60.3m70.9m76.2m67.5m116.4m

Total Equity

295.5m329.3m337.3m364.4m427.5m

Financial Leverage

1.3 x1.3 x1.3 x1.4 x1.4 x

Quarterly

USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Cash

64.1m72.9m68.6m74.5m70.7m63.3m66.7m66.6m76.8m82.5m66.9m54.5m48.1m68.7m79.1m120.4m85.6m54.8m

Accounts Receivable

18.6m26.6m21.7m19.8m25.0m23.1m23.1m26.6m25.9m24.1m24.2m31.9m41.3m43.8m54.9m48.8m45.3m57.8m

Prepaid Expenses

3.7m4.9m3.9m3.3m4.2m3.1m1.8m4.0m8.1m7.2m8.7m5.7m4.4m6.7m9.0m8.5m10.5m9.0m

Inventories

106.0m88.1m84.9m80.2m72.4m82.2m88.3m90.7m78.1m74.5m69.6m62.8m61.7m65.4m78.6m99.2m109.9m107.9m

Current Assets

214.2m215.2m202.6m203.9m199.1m173.4m181.3m190.2m191.4m193.6m176.5m174.0m169.9m194.8m230.1m284.1m268.9m246.7m

PP&E

134.0m134.1m138.3m139.3m141.2m144.7m148.6m152.0m157.4m161.7m173.0m191.9m198.2m202.5m214.8m220.1m222.2m231.5m

Goodwill

39.3m43.2m41.3m40.9m40.5m44.0m43.3m51.7m46.0m45.9m45.7m44.9m43.5m42.7m42.3m41.7m41.1m40.5m

Total Assets

397.3m401.1m396.5m398.9m395.0m395.0m408.6m428.8m435.6m444.0m437.8m449.8m451.6m480.6m544.7m601.3m585.6m572.8m

Accounts Payable

17.8m10.0m18.9m18.4m12.3m18.6m18.8m13.4m19.3m14.9m9.6m15.6m21.7m22.7m34.3m31.5m22.0m16.5m

Short-term debt

10.7m10.1m12.5m12.6m14.8m11.2m10.9m8.5m5.3m6.2m6.2m6.1m18.9m18.6m17.6m6.9m7.0m14.9m

Current Liabilities

56.3m63.1m72.1m69.4m70.7m64.9m65.7m60.8m72.9m63.7m57.4m72.5m87.6m96.6m112.0m101.0m86.6m83.4m

Long-term debt

42.9m41.3m35.9m34.8m31.4m29.1m31.7m34.2m31.1m40.1m42.2m39.7m33.7m32.6m42.1m57.5m55.0m51.6m

Total Debt

53.5m51.3m48.4m47.4m46.1m40.3m42.6m42.7m36.4m46.3m48.4m45.8m52.6m51.2m59.7m64.5m45.0m66.6m

Total Liabilities

109.5m118.0m117.2m113.7m111.2m98.4m101.1m100.4m110.1m110.7m107.1m122.7m131.1m139.4m164.5m169.0m152.0m149.5m

Common Stock

4.0k4.0k4.0k5.0k5.0k5.0k5.0k5.0k5.0k5.0k5.0k5.0k5.0k5.0k5.0k5.0k5.0k5.0k

Preferred Stock

Additional Paid-in Capital

217.0m219.3m223.3m236.7m240.7m250.7m258.8m276.5m285.4m299.1m303.2m316.7m322.4m330.3m349.2m355.4m361.7m371.1m

Retained Earnings

71.0m65.6m62.4m55.8m52.8m62.8m69.7m73.6m72.6m74.6m74.8m69.6m66.8m65.6m68.3m116.1m117.4m120.3m

Total Equity

287.7m283.1m279.3m285.3m283.8m296.6m307.5m328.5m325.6m333.3m330.7m327.1m320.5m341.3m380.3m432.3m433.7m423.4m

Debt to Equity Ratio

0.1 x

Debt to Assets Ratio

0.1 x

Financial Leverage

1.4 x1.4 x1.4 x1.4 x1.4 x1.3 x1.3 x1.3 x1.3 x1.3 x1.3 x1.4 x1.4 x1.4 x1.4 x1.4 x1.4 x1.4 x

Amphastar Pharmaceuticals Cash Flow

Annual

usdFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(10.7m)(2.8m)10.5m4.5m(6.7m)46.5m

Depreciation and Amortization

12.0m15.4m16.5m18.1m

Accounts Receivable

1.2m6.4m(8.1m)(16.3m)6.7m

Inventories

9.1m(9.7m)18.7m(6.0m)(41.1m)

Accounts Payable

7.0m6.7m29.2m(11.7m)

Cash From Operating Activities

14.2m(1.8m)38.6m39.2m38.2m41.8m

Purchases of PP&E

(18.7m)(35.1m)(46.8m)(41.6m)

Cash From Investing Activities

(39.8m)(39.5m)(38.8m)(42.2m)(50.5m)

Short-term Borrowings

(347.0k)

Long-term Borrowings

(8.2m)(14.7m)(9.7m)(5.7m)(6.4m)

Cash From Financing Activities

32.1m7.1m(7.7m)25.0m(3.8m)

Net Change in Cash

(6.8m)20.7m(12.7m)

Interest Paid

2.6m1.9m2.4m2.4m

Income Taxes Paid

436.0k3.4m4.9m339.0k5.7m

Quarterly

USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Net Income

(2.8m)(8.2m)(665.0k)(7.3m)(10.3m)2.5m9.4m13.3m893.0k2.9m3.0m(7.2m)(10.0m)(8.4m)(2.2m)44.8m45.8m3.5m

Depreciation and Amortization

7.0m10.7m3.3m6.6m10.0m3.4m7.0m10.8m3.8m7.7m11.5m3.9m8.0m12.1m4.5m8.8m13.3m5.0m

Accounts Receivable

6.0m(2.0m)621.0k2.5m(2.7m)10.2m10.2m6.8m920.0k2.8m2.9m4.6m(5.2m)(7.9m)(1.1m)1.7m6.7m(12.5m)

Inventories

(14.8m)1.6m(4.5m)564.0k8.5m(10.8m)(17.4m)(19.5m)1.9m7.0m12.4m1.4m1.6m(1.9m)(9.5m)(30.0m)(41.1m)2.2m

Accounts Payable

(2.7m)3.6m6.4m4.4m3.5m2.1m(1.9m)(2.8m)12.3m4.3m(2.0m)2.9m10.4m20.7m5.6m2.7m(8.3m)(5.7m)

Cash From Operating Activities

(4.9m)8.7m1.3m3.8m7.4m13.9m23.3m24.6m22.4m27.0m29.4m8.4m12.9m28.7m(3.6m)48.1m36.1m1.5m

Purchases of PP&E

(7.1m)(11.1m)(3.8m)(6.7m)(10.7m)(3.5m)(8.5m)(14.5m)(7.3m)(13.6m)(25.0m)(12.3m)(24.6m)(37.2m)(14.7m)(24.5m)(33.1m)(8.0m)

Cash From Investing Activities

(26.7m)(29.8m)(5.0m)(8.8m)(12.5m)(9.4m)(17.4m)(32.4m)(6.1m)(15.7m)(28.6m)(8.7m)(20.5m)(33.4m)(14.9m)(24.6m)(43.2m)(8.7m)

Short-term Borrowings

(40.0m)(40.0m)(347.0k)(347.0k)

Long-term Borrowings

(6.0m)(7.1m)(1.2m)(2.5m)(4.0m)(5.1m)(6.4m)(10.0m)(1.3m)(2.6m)(8.4m)(1.4m)(2.8m)(4.3m)(1.7m)(3.2m)(4.8m)(2.3m)

Cash From Financing Activities

42.1m40.7m4.4m11.5m7.8m(7.0m)(5.1m)8.4m(11.7m)(1.4m)(6.9m)(10.8m)(9.7m)8.1m11.2m10.5m6.6m(11.4m)

Net Change in Cash

10.5m19.3m760.0k6.6m2.9m(2.7m)586.0k524.0k4.4m10.2m(5.4m)(11.0m)(17.5m)3.1m(7.2m)34.0m(726.0k)(18.8m)

Interest Paid

573.0k978.0k469.0k897.0k1.3m517.0k947.0k1.4m390.0k792.0k1.3m532.0k1.1m1.7m898.0k1.3m1.9m559.0k

Income Taxes Paid

84.0k86.0k45.0k367.0k553.0k3.3m440.0k4.6m4.9m8.0k149.0k163.0k234.0k1.1m4.2m209.0k

Amphastar Pharmaceuticals Ratios

USDY, 2020

EV/EBIT

116.7 x

EV/CFO

591 x

Financial Leverage

1.4 x

Amphastar Pharmaceuticals Operating Metrics

FY, 2016

Facilities

5

Products

19

Amphastar Pharmaceuticals Employee Rating

2.353 votes
Culture & Values
1.9
Work/Life Balance
2.7
Senior Management
2.2
Salary & Benefits
2.3
Career Opportunities
2.0
Source